Danaher Corporation (DHR) Stock Score, Valuation & Financial Research
Danaher Corporation is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 34/100.
Quick answer for DHR
Danaher Corporation currently has a Wall Street Score of 34/100. The stored market price is $209.65. Its financial score is 19/100. Its valuation score is 10/100. These figures are a research snapshot, not a buy or sell recommendation.
What Danaher Corporation does
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, se
DHR financial snapshot
- Wall Street Score:
- 34/100
- Current price:
- $209.65
- Market capitalization:
- $147.38B
- Revenue:
- $25.11B
- Net income:
- $4.00B
- Free cash flow:
- $5.26B
- Cash:
- $4.35B
- Total debt:
- $26.56B
- EPS:
- 5.65
- P/E ratio:
- 37.1x
- Financial score:
- 19/100
- Valuation score:
- 10/100
- Revenue score:
- 14/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $5.26B, showing positive cash generation.
- The balance sheet shows $4.35B of cash versus $26.56B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 19/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research DHR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.